BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ProBioGen AG Introduces Novel Productivity-Boosting Technology for Therapeutic Protein Production: "Pathway Modulator"


6/14/2012 9:21:39 AM

Berlin, Germany, June 14, 2012 / B3C newswire / - ProBioGen announced the implementation of its new “Pathway Modulator Technology“, a permanent modification of animal cell lines for substantially improved protein yields. The Pathway Modulator Technology is royalty-free and available for new and existing cell lines either in service projects or as a license.

The Pathway Modulator Technology is highly versatile and quick: It is readily applicable to any animal cell line and, notably, even to existing producer cell lines, optimizing their productivity. The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells. Upon stable transfection, the modulator enzymes’ concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs. For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification enhanced yields between 1.5 and 2.6-fold.

The Pathway Modulator Technology can be installed into any existing cell lines, avoiding an entire new cell line development. It lowers upstream manufacturing costs and speeds up drug development through a more rapid supply of larger quantities of bulk drug substance.

The Pathway Modulator Technology can be freely combined with other parts of ProBioGen’s Tool Box, including the GlymaxX® ADCC Enhancement Technology, the stable CHO Evaluation Platform with DG44 and K1 cell lines, and the companies’ Full Pharmaceutical CHO Expression and Media Platform.

ProBioGen is actively seeking biopharmaceutical companies with hard-to-make protein drugs or with cell lines of insufficient productivities, to challenge their current yields.

About ProBioGen

ProBioGen is an internationally operating technology provider and Contract Development and Manufacturing Organization (CDMO) with almost 20 years of experience in cell culture, process development, and GMP-manufacturing. ProBioGen, with its scientific excellence and strong intellectual property base, is a competent and reliable CDMO partner, offering customized solutions for even the most challenging development and manufacturing requirements. This is backed by the company’s established, fee-for-service-based CHO cell and media platform, and its innovative platform technologies, such as GlymaxX® ADCC enhancement technology, the pathway modulator technology as well as the AGE1 family of animal and human designer cell lines, as well as its comprehensive portfolio of cell-based activity assays. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen was founded 1994 and is located in Berlin, Germany.

Contact ProBioGen

Dr Gabriele Schneider

Vice President Business Development

ProBioGen AG

Goethestrasse 54

13086 Berlin

Germany

Phone: +49 (0)30 924 006-0

Email: cmo@probiogen.de



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES